Boston, MA -- (SBWIRE) -- 10/04/2013 -- Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
- A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Bristol-Myers Squibb Company, Genzyme Corporation, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Seattle Genetics, Inc., Genentech, Inc., Gilead Sciences, Inc., Daiichi Sankyo Company, Ltd, medac GmbH, Merck & Co., Inc., Gamida Cell Ltd., Generex Biotechnology Corporation, Plexxikon Inc., BioLineRx, Ltd., Bio-Path Holdings, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sunesis Pharmaceuticals, Inc., SuperGen, Inc., Teva Pharmaceutical Industries Limited, Cell Therapeutics, Inc., Aduro BioTech, Cyclacel Pharmaceuticals Inc., Celgene Corporation, Incyte Corporation, Merck KGaA, 4SC AG, EntreMed, Inc., EpiCept Corporation, Celldex Therapeutics, Inc., IMMUNOMEDICS, INC, Ariad Pharmaceuticals, Inc., Lorus Therapeutics Inc, Marshall Edwards, Inc., MethylGene Inc, OXiGENE, Inc., Critical Outcome Technologies Inc., CSL Limited, Telik, Inc., TopoTarget A/S, VioQuest Pharmaceuticals, Inc., Lipoxen PLC, Choongwae Pharma Corp, Resverlogix Corp., Synta Pharmaceuticals Corp., BioAlliance Pharma SA, Sareum Holdings plc, Innate Pharma SA, Oscotec Inc., Stem Cell Therapeutics Corp., SymBio Pharmaceuticals Limited, Cellerant Therapeutics, Inc., Antigen Express, Inc., Cancer Research Technology Limited, Chroma Therapeutics Ltd., Colby Pharmaceutical Company, Ambit Biosciences Corporation, Actinium Pharmaceuticals, Inc., BioMAS Ltd., Oncodesign SA, ERYtech Pharma, Celator Pharmaceuticals, Inc., Altor BioScience Corporation, Ascenta Therapeutics, Inc., Coronado Biosciences, Inc., Agios Pharmaceuticals, TetraLogic Pharmaceuticals, Deciphera Pharmaceuticals, LLC, Affichem, Stemline Therapeutics, Inc., Proacta, Inc., Cornerstone Pharmaceuticals, Inc., Advenchen Laboratories, LLC, Onconova Therapeutics, Inc, Syndax Pharmaceuticals, Inc., NovaLead Pharma Pvt. Ltd., Esperance Pharmaceuticals, Inc., Trillium Therapeutics Inc., SBI Biotech Co., Ltd., KaloBios Pharmaceuticals, Inc., Aprea AB., Kinex Pharmaceuticals, LLC, OncoImmune, Inc., GlycoMimetics, Inc., Merus B.V., Toko Pharmaceutical Industries Co., Ltd., Cancer Therapeutics CRC Pty Ltd, Interprotein Corporation, EpiZyme, Inc., Targa Therapeutics Corp., NuCana BioMed Limited, Sentinel Oncology Limited, BerGenBio AS

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2013
- Acute Promyelocytic Leukemia - Pipeline Review, H2 2012
- Acute Promyelocytic Leukemia - Pipeline Review, H1 2013
- B-Cell Leukemia - Pipeline Review, H2 2013
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2013
- Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
- Acute Pain - Pipeline Review, H2 2013